Gilead Sciences (Nasdaq: GILD) has announced positive interim results from the ongoing ASSURE study of seladelpar.
The investigational PPAR delta agonist is being developed to reduce pruritus in people living with primary biliary cholangitis (PBC), an indication for which there are currently no approved medicines.
70% of people receiving seladelpar 10mg achieved the clinically meaningful composite endpoint and 37% achieved ALP normalization at 12 months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze